Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme

Glioblastoma multiforme is a malignant brain tumor with poor prognosis and high morbidity due to its invasiveness. Hypoxia-driven motility and concentration-driven motility are two mechanisms of glioblastoma multiforme invasion in the brain. The use of anti-angiogenic drugs has uncovered new progression patterns of glioblastoma multiforme associated with significant differences in overall survival. Here, we apply a mathematical model of glioblastoma multiforme growth and invasion in humans and design computational trials using agents that target angiogenesis, tumor replication rates, or motility. The findings link highly-dispersive, moderately-dispersive, and hypoxia-driven tumors to the patterns observed in glioblastoma multiforme treated by anti-angiogenesis, consisting of progression by Expanding FLAIR, Expanding FLAIR + Necrosis, and Expanding Necrosis, respectively. Furthermore, replication rate-reducing strategies (e.g. Tumor Treating Fields) appear to be effective in highly-dispersive and moderately-dispersive tumors but not in hypoxia-driven tumors. The latter may respond to motility-reducing agents. In a population computational trial, with all three phenotypes, a correlation was observed between the efficacy of the rate-reducing agent and the prolongation of overall survival times. This research highlights the potential applications of computational trials and supports new hypotheses on glioblastoma multiforme phenotypes and treatment options.

[1]  E. Papavassiliou,et al.  Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. , 1996, The Journal of clinical investigation.

[2]  P. Wen,et al.  Bevacizumab for glioblastoma , 2014, Neurology.

[3]  Kristin R. Swanson,et al.  Quantifying glioma cell growth and invasion in vitro , 2008, Math. Comput. Model..

[4]  T. Mikkelsen,et al.  Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy12 , 2014, Neoplasia.

[5]  H. Frieboes,et al.  Computer simulation of glioma growth and morphology , 2007, NeuroImage.

[6]  T. Cloughesy,et al.  A novel bicompartmental mathematical model of glioblastoma multiforme. , 2015, International journal of oncology.

[7]  W. Sessa,et al.  Antiangiogenic therapy: creating a unique "window" of opportunity. , 2004, Cancer cell.

[8]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[9]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[10]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[11]  E. Dekel,et al.  Disruption of cancer cell replication by alternating electric fields. , 2004, Cancer research.

[12]  N. Butowski,et al.  Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). , 2014, Seminars in oncology.

[13]  P. Basser,et al.  Predicting the electric field distribution in the brain for the treatment of glioblastoma , 2014, Physics in medicine and biology.

[14]  T. Seyfried,et al.  A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion , 2010, Journal of Neuro-Oncology.

[15]  Jonathan Lerner,et al.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression , 2007, Journal of Neuro-Oncology.

[16]  E. Dekel,et al.  Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors , 2007, Proceedings of the National Academy of Sciences.

[17]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[18]  Kristin R. Swanson,et al.  Virtual resection of gliomas: Effect of extent of resection on recurrence , 2003 .

[19]  Thierry Colin,et al.  A Multilayer Grow-or-Go Model for GBM: Effects of Invasive Cells and Anti-Angiogenesis on Growth , 2014, Bulletin of mathematical biology.

[20]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[21]  Myron D. Ginsberg,et al.  Neuroprotection for ischemic stroke: Past, present and future , 2008, Neuropharmacology.

[22]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[23]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[24]  H. Fathallah-Shaykh,et al.  c-Src and Neural Wiskott-Aldrich Syndrome Protein (N-WASP) Promote Low Oxygen-Induced Accelerated Brain Invasion by Gliomas , 2013, PloS one.

[25]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[26]  Alexander Radbruch,et al.  Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma , 2014, Neurology.

[27]  Hassan M. Fathallah-Shaykh,et al.  Effects of Anti-Angiogenesis on Glioblastoma Growth and Migration: Model to Clinical Predictions , 2014, PloS one.

[28]  Alexander R A Anderson,et al.  Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: in Silico Modeling Integrates Imaging and Histology Nih Public Access Author Manuscript Introduction , 2011 .

[29]  N. Cordes,et al.  Hypoxia-Induced Tumour Cell Migration in an in vivo Chicken Model , 2000, Pathobiology.

[30]  Hervé Delingette,et al.  Extrapolating glioma invasion margin in brain magnetic resonance images: Suggesting new irradiation margins , 2010, Medical Image Anal..

[31]  M. Weller,et al.  Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. , 2013, Neuro-oncology.

[32]  Erratum: Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe) (Seminars in Oncology (2014) 41:5 (S4-S13)) , 2015 .

[33]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[34]  Thomas C. Chen,et al.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. , 2015, JAMA.

[35]  D. Liebeskind,et al.  Trends in Acute Ischemic Stroke Trials Through the 20th Century , 2001, Stroke.

[36]  Andrew D J Pearson,et al.  How can attrition rates be reduced in cancer drug discovery? , 2013, Expert opinion on drug discovery.

[37]  E. Kostelich,et al.  Virtual glioblastoma: growth, migration and treatment in a three‐dimensional mathematical model , 2009, Cell proliferation.

[38]  Hervé Delingette,et al.  Image Guided Personalization of Reaction-Diffusion Type Tumor Growth Models Using Modified Anisotropic Eikonal Equations , 2010, IEEE Transactions on Medical Imaging.

[39]  Rakesh K Jain,et al.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. , 2012, Cold Spring Harbor perspectives in medicine.